Table 4 Pharmacokinetic parameters of 3′-deoxyinosine following intravenous and oral administration of cordycepin.

From: A novel nucleoside rescue metabolic pathway may be responsible for therapeutic effect of orally administered cordycepin

Route of administration

Intravenous

Oral

Dose (mg/kg)

8

20

8

80

C0 or Cmax (ng/mL)

5729 ± 1633

16347 ± 3871

202 ± 98

1280 ± 267

AUCinf (ng·h/mL)

723 ± 177

2736 ± 720

297 ± 69

1707 ± 555

AUCinf/Dose (ng·h·kg/mL/mg)a

90 ± 22

137 ± 36

37 ± 9

21 ± 7

Tmax (h)

—

—

0.25

0.5

t1/2 (h)

0.29 ± 0.09

0.80 ± 0.29

1.11 ± 0.39

0.85 ± 0.36

CL (L/h/kg)b

11.5 ± 2.7

7.8 ± 2.2

—

—

Vss (L/kg)

2.8 ± 0.3

3.0 ± 0.7

—

—

Foral (%)c

—

—

36.8 ± 11.3

—

  1. Cmax, maximum concentration observed, AUCinf, area under the concentration-time curve from time zero to infinity; Tmax, time of maximum concentration observed; t1/2, elimination half-life; Vss, volume of distribution at steady state; Foral, oral bioavailability of 3′-deoxyinosine achievable by administration of cordycepin. Refer to Table 3 for abbreviation of other parameters.
  2. aSignificant difference between AUCinf/Dose of 8 and 80 mg/kg oral administration groups was found (p < 0.05).
  3. bSignificant difference between CL of 8 and 20 mg/kg intravenous administration groups was found (p < 0.05).
Back to article page